Top Health Tech Companies (10,000+)

Strong Revenue Growth: Recent results show steady top-line expansion: FY2025 rose 9.3% and FY2026 quarters continued to grow in the mid‑single digits, with full‑year guidance at 4%–6%. Management indicates both U.S. and International Healthcare Solutions are expected to expand, sustaining momentum.

Profitability: Adjusted operating income and EPS increased at double‑digit rates (e.g., FY2025 AOI +15.8% and EPS +16.3%, with Q3 FY2026 EPS +12%), and guidance points to 13%–14% adjusted operating income growth. Outlook also includes solid adjusted free cash flow of around $3.0B.

Strong Market Position & Advantage: The company is consistently portrayed as one of the three dominant U.S. pharmaceutical distributors, reflecting scale, reach, and entrenched relationships. This position supports durable volumes in specialty categories and international distribution.

Strong Revenue Growth: Revenue increased 19% in 2025 and accelerated in 2026 with 22% year-over-year growth in Q1 and 27% in Q2, while first-half 2026 revenue rose 25% year over year. Management raised full-year 2026 guidance to $94–96M, implying roughly 22–24% growth.

Customer Loyalty & Retention: Net Dollar Retention reached 117% in Q1 2026, indicating expanding spend from existing accounts after churn. Core genomics customers rose to 537 as of March 31, 2026, with record new customer additions in 2025.

Market Expansion: Geographic momentum is evident with Q1 2026 analysis volume up 28% in the U.S. and 31% in APAC, and EMEA revenue up 30%. Platform usage set records (e.g., 108,000 analyses in Q1 and 115,000 in Q2), with liquid biopsy volumes growing sharply.

Strong Revenue Growth: Revenue is reported as expanding rapidly, with more than 60% year-over-year growth in committed ARR in 2024. External recognitions like Deloitte Technology Fast 500 and repeat Inc. 5000 placements point to sustained multi-year momentum.

Market Expansion: New health plan partnerships and an increase to 17 health plans by 2026, alongside 12 million annual prior authorizations and 25M covered lives, indicate a widening commercial footprint. Integrations such as Epic’s Payer Platform and expanded relationships with national and regional plans reinforce adoption.

Investor Backing & Capital Strength: A $90 million Series C in 2025 brought total funding to roughly $200 million. Successive raises and participation from prominent investors suggest ample capital to support scaling.

Market Expansion: National and payer footprint have broadened materially, with availability across all 50 states, plan relationships rising toward 100+, and sharp increases in providers, patients, and appointments. This widening reach indicates an ability to capture demand across geographies and insurance lines.

Investor Backing & Capital Strength: A $100M Series D at a roughly $2.3B valuation alongside substantial prior financing reflects strong access to growth capital. This position supports continued scaling of the network, product investments, and deeper insurer integrations.

Strong Revenue Growth: Revenue is described as having increased significantly over a recent 12‑month period, with earlier disclosures citing outsized year‑over‑year gains. Coupled with rising session volumes, this points to robust top‑line momentum despite limited public financial detail.

Strong Revenue Growth: Revenue is rising at a double‑digit pace across 2025 and into 2026, with consistent year‑over‑year gains. Galleri test volumes and screening revenue also increased, signaling sustained commercial momentum.

Market Expansion: Access is broadening through major EHR integrations and a growing provider network, alongside initiatives to enter new geographies. These moves extend reach beyond core channels and support continued adoption.

Investor Backing & Capital Strength: Capital raises and a sizable cash position provide a multi‑year runway to fund commercialization, trials, and regulatory efforts. Strategic financings with prominent partners reinforce the ability to invest through scale‑up.

Strong Revenue Growth: Available disclosures indicate revenue grew at a triple‑digit rate year over year in early 2026 and was later described as roughly $200M after multiple years of doubling. These signals point to rapid scaling beyond a purely funding‑led story.

Investor Backing & Capital Strength: Back‑to‑back late‑stage rounds in 2026, including a nine‑figure Series D followed quickly by a nine‑figure Series E with a stepped‑up valuation, suggest deep capital access and investor conviction. The rapid valuation increase provides additional financial flexibility for expansion.

Strategic Partnerships: Announcements in 2026 with organizations such as Atlantic Health and Priority Health indicate expanding distribution channels beyond direct employer sales. These relationships broaden market reach and embed the offering within health systems and plans.

Strong Revenue Growth: Company-reported results indicate 34% year-over-year software growth in 2024, alongside earlier periods of 100% YoY elluminate software growth in 2022 and 50% in 2021. These signals point to sustained momentum in the software business.

Market Expansion: The organization added 20 net-new clients in 2024 and more than 20 in 2025, with its footprint among top global pharma expanding from 16 to 18 of the world’s top 50 companies. This reflects a widening customer base across large enterprise accounts.

Investor Backing & Capital Strength: A September 2024 majority investment by GI Partners—described as a growth investment—with previous investor Summit Partners retaining a minority stake indicates strong institutional support. Subsequent expansion of the executive team aligns with funding to drive the next phase of growth.

Investor Backing & Capital Strength: Funding momentum is pronounced, with a $35M Series A (Mar 2025), $100M Series B (Sep 2025), and a $70M Series C (Sep 2026) bringing total capital to about $225M at a valuation above $500M. This pattern signals sustained investor appetite and a materially stronger capital position.

Strong Revenue Growth: Reporting indicates subscription revenue nearly quadrupled year over year to about $29M, while contracted revenue surpassed $60M. These figures point to rapid scaling of recurring and booked revenue.

Market Expansion: Commercial reach appears to be growing, with monitoring of roughly 40,000 residents across just over 500 senior-living communities and new deployments among named operators. Expanding partnerships and portfolio rollouts suggest a widening customer footprint.

Strong Revenue Growth: Revenue is reported to have expanded dramatically over a recent three-year period, earning recognition on a leading high-growth list. Feedback suggests this reflects substantial commercial traction rather than growth based solely on financing.

Strong Market Position & Advantage: Customer adoption spans 500+ MedTech companies, including deep penetration among the largest enterprises (e.g., 16 of the top 20). Feedback suggests this breadth and upmarket presence signal durable positioning within its niche.

Investor Backing & Capital Strength: Capital raised has surpassed $160M with a recent late-stage round and a valuation near the unicorn threshold. Feedback suggests this funding base supports continued product expansion, AI initiatives, and go-to-market scale.

Investor Backing & Capital Strength: Evidence indicates a $55M Series B in 2026 brought cumulative funding above $73M to accelerate hiring, R&D, and platform adoption. This capital position supports scaling operations and product development.

Strong Revenue Growth: Company materials state revenue increased 4× in the 12 months prior to April 2024, with earlier periods citing 24× growth and expectations to more than double in 2022. These signals indicate rapid top-line expansion, though current figures are not independently audited.

Product Line Growth: The offering has expanded beyond payment integrity into utilization management and appeals while launching AI agents for DRG validation, readmissions, and emergency-department reviews. This broadening scope increases relevance across health‑plan claims workflows.

Strong Revenue Growth: Revenue is reported to have surpassed $750 million in 2025, up 45% year over year, with momentum indicated into 2026. More than 10 million people made purchases through the platform in 2025, aligning with the topline expansion.

Profitability: The company recorded its eighth consecutive profitable year in 2025, indicating expansion with positive economics. This profitability streak accompanies the recent revenue step-up.

Diversified Revenue Streams: Growth extends beyond the core registry, with Health revenue up 64% and Media up 35% in 2025. Physical showrooms, a large fulfillment center, and media/content initiatives further broaden monetization.

Strong Revenue Growth: TechCrunch reported that revenue increased six-fold year over year as of May 2025, indicating rapid top-line acceleration.

Market Expansion: The company expanded from 5 states in 2023 to 18 states in 2025 and announced nearly 25 states by February 2026, pointing to broadening geographic coverage.

Investor Backing & Capital Strength: The company closed a $55 million Series B in May 2025, bringing total funding to about $125 million. The round was led by General Catalyst with participation from Andreessen Horowitz, GV, and Accel, underscoring access to capital.

Market Expansion: Reported enrollments of roughly 250,000 in 2025 and a broker base exceeding 10,000 point to a rapidly widening operating footprint. AEP 2025 production metrics and tens of thousands of contracts processed further suggest the platform is scaling beyond its 2024 funding milestone.

Investor Backing & Capital Strength: A $25M Series B in January 2024, reportedly at a significant valuation step-up, underscores access to growth capital. Independent listings also record total funding in the high-$30Ms range, reinforcing external validation of capitalization.

Strong Hiring & Retention: Headcount reportedly expanded from around 40 to roughly 130 by 2025, and current postings include senior roles across revenue operations, engineering, product, and agent/customer experience. Active requisitions signal continued investment in growth infrastructure.

Market Expansion: Adoption appears to have increased from 19,000+ hospitals in June 2023 to 23,000+ currently, indicating continued penetration of the U.S. veterinary market. The platform is also described as powering purchasing infrastructure for the majority of several practice types nationwide.

Product Line Growth: The offering has expanded from a price-comparison tool into a broader procurement ecosystem spanning distributors, manufacturers, and diagnostic labs, with a catalog covering 99.9% of products veterinarians use. This evolution points to a shift toward comprehensive procurement infrastructure rather than a single-point solution.

Strong Market Position & Advantage: A 23,000+ hospital installed base and a supplier-side marketplace marketed as access to 23,000+ clinics suggest reinforcing network effects. Monetization on the supplier/manufacturer side and corporate capabilities further underscore centrality in the purchasing workflow.

Strong Revenue Growth: Revenue is reported to have surpassed the $100 million annual mark with continued year-over-year gains. Feedback suggests momentum is reinforced by growth in newer verticals such as education and hospitality.

Market Expansion: The company extended its footprint from North America into the UK and Ireland and broadened placements beyond offices into campuses, hotels, gyms, warehouses, and other venues, while scaling to more than 6,000 customers. Feedback suggests international entry and vertical diversification are driving a larger installed base and usage milestones such as surpassing one billion single-use containers avoided.

Product Line Growth: The offering advanced from smart water coolers to a connected beverage platform, adding functional enhancements and a better-for-you soda line alongside new countertop hardware. Feedback suggests the expanded menu increases relevance across more locations and upsell potential within existing accounts.

Market Expansion: Granted is extending beyond direct-to-consumer into institutional channels, launching a North Texas educator program initially covering 5,000+ Mesquite ISD employees with additional districts expected. A September 2026 rollout of Clear the Bill further signals targeted regional program expansion.

Strategic Partnerships: Collaborations with First Financial Group of America and StretchDollar are broadening access through employer and benefits distribution. These partnerships are described as recent commercial expansions and the company’s first school‑district collaboration.

Investor Backing & Capital Strength: The company secured approximately $16.25M–$16.3M in a 2024 Series A/financing, cited by multiple industry sources. This level of backing indicates meaningful investor support for continued development and scaling.

Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.

Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.

Strong Revenue Growth: Revenue is reported to have grown 4× in 2023, more than 300% in 2024, and then doubled again in 2025, indicating sustained acceleration. Company communications consistently point to multi‑year, triple‑digit expansion across successive periods.

Investor Backing & Capital Strength: Capital raised includes a $47M Series B in 2024 and a $72M Series C in 2025, bringing total funding to $162M. This level of financing from institutional and strategic investors signals ample resources to support scale.

Strategic Partnerships: Partnerships are described with 7–8 of the top 10 U.S. life insurers and additional organizations such as Prudential, Principal, and Aflac. This enterprise-led distribution has extended access to tens of millions of policyholders and employees.

Strong Revenue Growth: Revenue is described as sizable and growing rapidly, with independent reporting and credit analyses pointing to continued double‑digit expansion. ARR and ACV are characterized as increasing consistently since 2022.

Customer Loyalty & Retention: Retention is depicted as very high, with consistent expansion within existing accounts that supports sustained recurring revenue growth. Commentary highlights strong share‑of‑wallet gains and durable renewals across healthcare customers.

Product Line Growth: The portfolio has broadened through repeated acquisitions (e.g., SecureLink, Verosint) and new capabilities such as passwordless authentication and agentic identity management. These moves signal active investment to expand addressable use cases and deepen the platform.

Strong Hiring & Retention: Hiring and headcount are expanding, with disclosures of 15,000+ global employees, thousands of new hires, and third‑party estimates indicating continued workforce growth. Available evidence also points to active internal mobility and a recent increase in active job postings.

Market Expansion: Geographic and client footprints are broadening, with 40+ offices and 1,700+ customers across 170+ countries alongside concrete investments in new and expanded locations such as Hyderabad and Kingston. These moves indicate scaling delivery capacity in major capability centers and new regions.

Innovation-Driven Growth: The offering mix is shifting toward AI, data, technology, and platforms, including proprietary solutions and product capabilities. Strategic moves such as Salesforce-focused acquisitions and collaborations, plus a Tulip solution partnership, extend capabilities beyond traditional consulting.